Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study
Weiyou Zhu(Jiangsu Province Hospital), Xiaofeng Chen(Ningbo University), Renhua Guo(Sun Yat-sen University), Yongqian Shu(Jiangsu Province Hospital), Chen Wu(University of Electronic Science and Technology of China), Yiqian Liu(Jiangsu Province Hospital), Yanhong Gu(Nanjing Medical University), Wei Li(Shanghai Jiao Tong University), Oluf Dimitri Røe(Norwegian University of Science and Technology)
Cited by 9
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311